Barbigerone prevents scopolamine-induced memory impairment in rats by inhibiting oxidative stress and acetylcholinesterase levels.
Shareefa A AlGhamdiFahad A Al-AbbasiAmira M AlghamdiAsma B OmerObaid AfzalAbdulmalik S A AltamimiAbdulaziz AlamriSami I AlzareaWaleed Hassan AlmalkiImran KazmiPublished in: Royal Society open science (2023)
The current study was designed for the evaluation of barbigerone on memory loss. In this experimental study, 24 Wistar rats ( n = 6) were used. Control rats and scopolamine (SCOP)-treated control group rats were orally administered with 3 ml of 0.5% sodium carboxymethyl cellulose (vehicle), whereas barbigerone was (10 and 20 mg kg -1 ) administered orally to the rats from the test group. During the 14-day treatment, control group rats were given 3 ml kg -1 day -1 saline, and all other groups were administered SCOP (1 mg kg -1 day -1 , i.p.) 1 h after barbigerone p.o. treatment. The spontaneous alternation activities, learning capacities of a rat's memory were tested with Morris water maze and Y-maze. Reduced glutathione, malondialdehyde, acetylcholine esterase (AChE) and catalase (CAT) levels were measured in rat brain tissue as oxidative stress/antioxidant markers. Moreover, the levels of tumour necrosis factor, interleukin-6 (IL-6) and IL-1 β were also estimated. Treatment with barbigerone in SCOP-administered rats dramatically reduced SCOP-induced neurobehavioural deficits, oxidative stress and neuroinflammatory markers, improved endogenous antioxidants, and restored AChE activity. By improving cholinergic function and reducing oxidative damage, barbigerone could mitigate the effects of SCOP-induced changes in the brain.